Abstract
The U.S. Food and Drug Administration is warning companies for illegally selling cannabidiol (CBD) by claiming that the product can treat opioid addiction or be used as an alternative to opioids. These claims violate the law, and the warning letters are a continuation of the FDA's efforts to pursue companies that illegally market CBD products with claims that they can treat medical conditions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
